It’s a long way to the top (if you want to personalize immunotherapy)
Harnessing the immune system to attack tumor cells by targeting tumor-associated or –preferably– tumor-specific antigens has emerged as a promising but challenging treatment option for malignant lymphomas. Follicular lymphoma is among the most common lymphomas worldwide and remains incurable for mos...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2017-08-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/5/1/6.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849720857555894272 |
|---|---|
| author | Sarah Haebe Oliver Weigert |
| author_facet | Sarah Haebe Oliver Weigert |
| author_sort | Sarah Haebe |
| collection | DOAJ |
| description | Harnessing the immune system to attack tumor cells by targeting tumor-associated or –preferably– tumor-specific antigens has emerged as a promising but challenging treatment option for malignant lymphomas. Follicular lymphoma is among the most common lymphomas worldwide and remains incurable for most patients. Considered to be an immunogenic disease it represents an interesting disease entity for various immunotherapeutic approaches.In an article published in the May issue of Clinical Cancer Research, Nielsen and colleagues provided important proof-of-principle data on the immunogenicity of follicular lymphoma that might represent a first step towards personalized adoptive immunotherapies in this disease. The authors combined targeted next-generation sequencing and in silico analyses to explore the concept of somatic neoepitope prediction. Neoantigen-specific CD8+ T-cells could be identified in a small subset of patients selected for in vitro immunogenicity experiments, however at remarkably low frequencies and in only a few patients at single time-points. Of note, the immunogenic neoepitopes were derived from mutant CREBBP and MEF2B, two genes that have previously been shown to be functionally and prognostically relevant in this disease.In this commentary we discuss the promises but also the challenges of how to translate these findings into clinical practice. |
| format | Article |
| id | doaj-art-2306bc2124644fa69fedc1fb7d971a53 |
| institution | DOAJ |
| issn | 2051-1426 |
| language | English |
| publishDate | 2017-08-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-2306bc2124644fa69fedc1fb7d971a532025-08-20T03:11:51ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262017-08-015110.1186/s40425-016-0207-0It’s a long way to the top (if you want to personalize immunotherapy)Sarah Haebe0Oliver Weigert1Aff1 grid.5252.0000000041936973XDepartment of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF)Ludwig-Maximilians-University Max-Lebsche Platz 30 81377 Munich GermanyAff1 grid.5252.0000000041936973XDepartment of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF)Ludwig-Maximilians-University Max-Lebsche Platz 30 81377 Munich GermanyHarnessing the immune system to attack tumor cells by targeting tumor-associated or –preferably– tumor-specific antigens has emerged as a promising but challenging treatment option for malignant lymphomas. Follicular lymphoma is among the most common lymphomas worldwide and remains incurable for most patients. Considered to be an immunogenic disease it represents an interesting disease entity for various immunotherapeutic approaches.In an article published in the May issue of Clinical Cancer Research, Nielsen and colleagues provided important proof-of-principle data on the immunogenicity of follicular lymphoma that might represent a first step towards personalized adoptive immunotherapies in this disease. The authors combined targeted next-generation sequencing and in silico analyses to explore the concept of somatic neoepitope prediction. Neoantigen-specific CD8+ T-cells could be identified in a small subset of patients selected for in vitro immunogenicity experiments, however at remarkably low frequencies and in only a few patients at single time-points. Of note, the immunogenic neoepitopes were derived from mutant CREBBP and MEF2B, two genes that have previously been shown to be functionally and prognostically relevant in this disease.In this commentary we discuss the promises but also the challenges of how to translate these findings into clinical practice.https://jitc.bmj.com/content/5/1/6.full |
| spellingShingle | Sarah Haebe Oliver Weigert It’s a long way to the top (if you want to personalize immunotherapy) Journal for ImmunoTherapy of Cancer |
| title | It’s a long way to the top (if you want to personalize immunotherapy) |
| title_full | It’s a long way to the top (if you want to personalize immunotherapy) |
| title_fullStr | It’s a long way to the top (if you want to personalize immunotherapy) |
| title_full_unstemmed | It’s a long way to the top (if you want to personalize immunotherapy) |
| title_short | It’s a long way to the top (if you want to personalize immunotherapy) |
| title_sort | it s a long way to the top if you want to personalize immunotherapy |
| url | https://jitc.bmj.com/content/5/1/6.full |
| work_keys_str_mv | AT sarahhaebe itsalongwaytothetopifyouwanttopersonalizeimmunotherapy AT oliverweigert itsalongwaytothetopifyouwanttopersonalizeimmunotherapy |